{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:16:26Z","timestamp":1788243386667,"version":"build-2803163510"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100030993","name":"Universit\u00e0 della Svizzera italiana","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030993","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40265-026-02355-5","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:50:00Z","timestamp":1785340200000},"page":"1489-1511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives"],"prefix":"10.1007","volume":"86","author":[{"given":"Giovanna","family":"Pecoraro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Montelatici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Salfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himisha","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul Raj","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild","family":"von Amsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Joerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Imbimbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8502-8226","authenticated-orcid":false,"given":"Martino","family":"Pedrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"issue":"7","key":"2355_CR1","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/ijc.35278","volume":"156","author":"AM Filho","year":"2022","unstructured":"Filho AM, Laversanne M, Ferlay J, Colombet M, Pi\u00f1eros M, Znaor A, et al. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer. 2025;156(7):1336\u201346. https:\/\/doi.org\/10.1002\/ijc.35278.","journal-title":"Int J Cancer"},{"issue":"1","key":"2355_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA A Cancer J Clinicians. 2025;75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA A Cancer J Clinicians"},{"issue":"10437","key":"2355_CR3","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403(10437):1683\u2013722. https:\/\/doi.org\/10.1016\/S0140-6736(24)00651-2.","journal-title":"Lancet"},{"issue":"11","key":"2355_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","volume":"23","author":"DE Spratt","year":"2025","unstructured":"Spratt DE, Srinivas S, Adra N, Ahmed B, An Y, Bitting R, et al. Prostate cancer, version 3.2026, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2025;23(11):469\u201393. https:\/\/doi.org\/10.6004\/jnccn.2025.0052.","journal-title":"J Natl Compr Canc Netw"},{"key":"2355_CR5","unstructured":"EAU Guidelines. Edn. In: Presented at the EAU annual congress, London. 2026."},{"issue":"23","key":"2355_CR6","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res. 2019;25(23):6916\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1423.","journal-title":"Clin Cancer Res"},{"key":"2355_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2026.01.011","author":"M Pedrani","year":"2026","unstructured":"Pedrani M, Salfi G, Pecoraro G, Puglisi M, Turco F, Tortola L, et al. Prognosis and treatment response in aggressive-variant prostate cancer and treatment-related neuroendocrine prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2026. https:\/\/doi.org\/10.1016\/j.euo.2026.01.011.","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"2355_CR8","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","volume":"22","author":"AM Aparicio","year":"2016","unstructured":"Aparicio AM, Shen L, Tapia ELN, Lu JF, Chen HC, Zhang J, et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin Cancer Res. 2016;22(6):1520\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1259.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2355_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/bco2.212","volume":"4","author":"J Chen","year":"2023","unstructured":"Chen J, Shi M, Chuen Choi SY, Wang Y, Lin D, Zeng H. Genomic alterations in neuroendocrine prostate cancer: a systematic review and meta\u2010analysis. BJUI Compass. 2023;4(3):256\u201365. https:\/\/doi.org\/10.1002\/bco2.212.","journal-title":"BJUI Compass"},{"issue":"2","key":"2355_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","volume":"23","author":"Y Yamada","year":"2021","unstructured":"Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep. 2021;23(2):15. https:\/\/doi.org\/10.1007\/s11912-020-01003-9.","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"2355_CR11","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Investig. 2019;129(10):4492\u2013505. https:\/\/doi.org\/10.1172\/JCI128212.","journal-title":"J Clin Investig"},{"issue":"5","key":"2355_CR12","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","volume":"82","author":"H Moch","year":"2022","unstructured":"Netto GJ, Amin MB, Berney DM, Comp\u00e9rat EM, Gill AJ, Hartmann A, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs\u2014Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022;82(5):469\u2013482. https:\/\/doi.org\/10.1016\/j.eururo.2022.07.002.","journal-title":"Eur Urol"},{"issue":"1","key":"2355_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115\u201354. https:\/\/doi.org\/10.1007\/s12022-022-09708-2.","journal-title":"Endocr Pathol"},{"issue":"1","key":"2355_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-026-04482-7","volume":"17","author":"EF Giunta","year":"2026","unstructured":"Giunta EF, Schepisi G, Bleve S, Serra R, Brighi N, Torresan I, et al. Neuroendocrine prostate cancer (NEPC) in focus: state of the art and future prospectives. Discov Oncol. 2026;17(1):457. https:\/\/doi.org\/10.1007\/s12672-026-04482-7.","journal-title":"Discov Oncol"},{"issue":"24","key":"2355_CR15","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018;36(24):2492\u2013503. https:\/\/doi.org\/10.1200\/JCO.2017.77.6880.","journal-title":"J Clin Oncol"},{"key":"2355_CR16","unstructured":"EAU Guidelines. Edn. In: Presented at the EAU annual congress, Madrid. 2025."},{"issue":"16_suppl","key":"2355_CR17","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.1200\/JCO.2025.43.16_suppl.5059","volume":"43","author":"G Von Amsberg","year":"2025","unstructured":"Von Amsberg G, Emmenegger U, Robbrecht DG, Arslan C, Mehra N, Gonzalez-Billalabeitia E, et al. Phase 1b\/2 KEYNOTE-365 cohort I: pembrolizumab (pembro) plus carboplatin and etoposide chemotherapy (chemo) or chemo alone for metastatic neuroendocrine prostate cancer (NEPC). JCO. 2025;43(16_suppl):5059\u20135059. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.5059.","journal-title":"JCO"},{"issue":"1","key":"2355_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0745-2","volume":"12","author":"DH Owen","year":"2019","unstructured":"Owen DH, Giffin MJ, Bailis JM, Smit MAD, Carbone DP, He K. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol. 2019;12(1):61. https:\/\/doi.org\/10.1186\/s13045-019-0745-2.","journal-title":"J Hematol Oncol"},{"issue":"16","key":"2355_CR19","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","volume":"41","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study. J Clin Oncol. 2023;41(16):2893\u2013903. https:\/\/doi.org\/10.1200\/JCO.22.02823.","journal-title":"J Clin Oncol"},{"key":"2355_CR20","unstructured":"The Human Protein Atlas. DLL3 (delta like canonical Notch ligand 3). [Internet]. https:\/\/www.proteinatlas.org\/ENSG00000090932-DLL3."},{"issue":"6","key":"2355_CR21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1083\/jcb.200503113","volume":"170","author":"E Ladi","year":"2005","unstructured":"Ladi E, Nichols JT, Ge W, Miyamoto A, Yao C, Yang LT, et al. The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands. J Cell Biol. 2005;170(6):983\u201392. https:\/\/doi.org\/10.1083\/jcb.200503113.","journal-title":"J Cell Biol"},{"issue":"1","key":"2355_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00934-y","volume":"7","author":"B Zhou","year":"2022","unstructured":"Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K, et al. Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Ther. 2022;7(1):95. https:\/\/doi.org\/10.1038\/s41392-022-00934-y.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2355_CR23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1146\/annurev.cellbio.19.111301.115434","volume":"19","author":"G Weinmaster","year":"2003","unstructured":"Weinmaster G, Kintner C. Modulation of notch signaling during somitogenesis. Annu Rev Cell Dev Biol. 2003;19(1):367\u201395. https:\/\/doi.org\/10.1146\/annurev.cellbio.19.111301.115434.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"11","key":"2355_CR24","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/oncolo\/oyac161","volume":"27","author":"J Yao","year":"2022","unstructured":"Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, et al. DLL3 as an emerging target for the treatment of neuroendocrine neoplasms. Oncologist. 2022;27(11):940\u201351. https:\/\/doi.org\/10.1093\/oncolo\/oyac161.","journal-title":"Oncologist"},{"issue":"4","key":"2355_CR25","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3390\/pharmaceutics17040520","volume":"17","author":"H Wang","year":"2025","unstructured":"Wang H, Zheng T, Xu D, Sun C, Huang D, Liu X. Targeting DLL3: innovative strategies for tumor treatment. Pharmaceutics. 2025;17(4):520. https:\/\/doi.org\/10.3390\/pharmaceutics17040520.","journal-title":"Pharmaceutics"},{"issue":"1","key":"2355_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00599-6","volume":"8","author":"A Ajkunic","year":"2024","unstructured":"Ajkunic A, Sayar E, Roudier MP, Patel RA, Coleman IM, De Sarkar N, et al. Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: expression landscape and molecular correlates. NPJ Precis Onc. 2024;8(1):104. https:\/\/doi.org\/10.1038\/s41698-024-00599-6.","journal-title":"NPJ Precis Onc"},{"issue":"17","key":"2355_CR27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175217","volume":"134","author":"SY Ku","year":"2024","unstructured":"Ku SY, Wang Y, Garcia MM, Yamada Y, Mizuno K, Long MD, et al. Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer. J Clin Investig. 2024;134(17):e175217. https:\/\/doi.org\/10.1172\/JCI175217.","journal-title":"J Clin Investig"},{"issue":"484","key":"2355_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav0891","volume":"11","author":"L Puca","year":"2019","unstructured":"Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med. 2019;11(484):eaav0891. https:\/\/doi.org\/10.1126\/scitranslmed.aav0891.","journal-title":"Sci Transl Med"},{"issue":"6","key":"2355_CR29","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41585-019-0190-6","volume":"16","author":"C Thoma","year":"2019","unstructured":"Thoma C. Targeting DLL3 in neuroendocrine prostate cancer. Nat Rev Urol. 2019;16(6):330\u2013330. https:\/\/doi.org\/10.1038\/s41585-019-0190-6.","journal-title":"Nat Rev Urol"},{"issue":"12_Supplement","key":"2355_CR30","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1158\/1538-7445.AM2022-2896","volume":"82","author":"SY Ku","year":"2022","unstructured":"Ku SY, Yamada Y, Ng P, Sun L, Beltran H. Abstract 2896: DLL3-targeted T cell engager therapy (HPN328) for neuroendocrine prostate cancer. Cancer Res. 2022;82(12_Supplement):2896\u20132896. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-2896.","journal-title":"Cancer Res"},{"issue":"2","key":"2355_CR31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1158\/1535-7163.MCT-25-0453","volume":"25","author":"SY Ku","year":"2026","unstructured":"Ku SY, Manzar N, Garcia MM, Kim MJ, Einstein DJ, Balk SP, et al. Preclinical activity of the DLL3-targeted T-cell engager MK-6070 in neuroendocrine prostate cancer. Mol Cancer Ther. 2026;25(2):346\u201354. https:\/\/doi.org\/10.1158\/1535-7163.MCT-25-0453.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2355_CR32","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1158\/2767-9764.CRC-24-0501","volume":"5","author":"JR Lozada","year":"2025","unstructured":"Lozada JR, Elliott A, Evans MG, Wacker J, Storey KM, Egusa EA, et al. Expression patterns of DLL3 across neuroendocrine and non-neuroendocrine neoplasms reveal broad opportunities for therapeutic targeting. Cancer Res Commun. 2025;5(2):318\u201326. https:\/\/doi.org\/10.1158\/2767-9764.CRC-24-0501.","journal-title":"Cancer Res Commun"},{"issue":"1","key":"2355_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51156-5","volume":"15","author":"VB Venkadakrishnan","year":"2024","unstructured":"Venkadakrishnan VB, Presser AG, Singh R, Booker MA, Traphagen NA, Weng K, et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Nat Commun. 2024;15(1):6779. https:\/\/doi.org\/10.1038\/s41467-024-51156-5.","journal-title":"Nat Commun"},{"issue":"1","key":"2355_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-69308-0","volume":"17","author":"R Singh","year":"2026","unstructured":"Singh R, Venkadakrishnan VB, Imada E, Yamada Y, Brady NJ, Dunmore KE, et al. Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity. Nat Commun. 2026;17(1):2992. https:\/\/doi.org\/10.1038\/s41467-026-69308-0.","journal-title":"Nat Commun"},{"issue":"1","key":"2355_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","volume":"7","author":"JL Bishop","year":"2017","unstructured":"Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, et al. The master neural transcription factor BRN2 is an androgen receptor\u2013suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 2017;7(1):54\u201371. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1263.","journal-title":"Cancer Discov"},{"issue":"28","key":"2355_CR36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2322203121","volume":"121","author":"S Zaidi","year":"2024","unstructured":"Zaidi S, Park J, Chan JM, Roudier MP, Zhao JL, Gopalan A, et al. Single-cell analysis of treatment-resistant prostate cancer: implications of cell state changes for cell surface antigen\u2013targeted therapies. Proc Natl Acad Sci USA. 2024;121(28):e2322203121. https:\/\/doi.org\/10.1073\/pnas.2322203121.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2355_CR37","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1158\/0008-5472.CAN-22-1433","volume":"83","author":"J Chou","year":"2023","unstructured":"Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, et al. Immunotherapeutic targeting and PET imaging of DLL3 in small-cell neuroendocrine prostate cancer. Cancer Res. 2023;83(2):301\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-1433.","journal-title":"Cancer Res"},{"issue":"1","key":"2355_CR38","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s40364-024-00698-3","volume":"12","author":"L Bonstingl","year":"2024","unstructured":"Bonstingl L, Zinnegger M, Sallinger K, Pankratz K, M\u00fcller CT, Pritz E, et al. Correction: advanced single-cell and spatial analysis with high-multiplex characterization of circulating tumor cells and tumor tissue in prostate cancer: unveiling resistance mechanisms with the CoDuCo in situ assay. Biomark Res. 2024;12(1):150. https:\/\/doi.org\/10.1186\/s40364-024-00698-3.","journal-title":"Biomark Res."},{"key":"2355_CR39","doi-asserted-by":"publisher","unstructured":"Capdevila J, Gambardella V, Kuboki Y, Alese OB, Morgensztern D, Sayehli C, et al. Efficacy and safety of the DLL3\/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: results from an ongoing phase I trial. J Clin Oncol. 2025;43(16_suppl):3004. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3004\n.","DOI":"10.1200\/JCO.2025.43.16_suppl.3004"},{"issue":"1","key":"2355_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00214-y","volume":"5","author":"AS Mansfield","year":"2021","unstructured":"Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, et al. A phase I\/II study of rovalpituzumab tesirine in delta-like 3\u2014expressing advanced solid tumors. npj Precis Onc. 2021;5(1):74. https:\/\/doi.org\/10.1038\/s41698-021-00214-y.","journal-title":"npj Precis Onc"},{"issue":"18","key":"2355_CR41","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-25-1211","volume":"31","author":"R Aggarwal","year":"2025","unstructured":"Aggarwal R, Rottey S, Bernard-Tessier A, Mellado B, Kosaka T, Stadler WM, et al. Safety and efficacy of tarlatamab in patients with neuroendocrine prostate cancer: results from the phase 1b DeLLpro-300 study. Clin Cancer Res. 2025;31(18):3854\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-1211.","journal-title":"Clin Cancer Res"},{"issue":"7_suppl","key":"2355_CR42","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1200\/JCO.2026.44.7_suppl.182","volume":"44","author":"H Beltran","year":"2026","unstructured":"Beltran H, Cooper AJ, Sankar K, Garmezy B, Jain P, Brown JR, et al. Efficacy and safety of the DLL3 T-cell engager gocatamig in participants (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN). J Clin Oncol. 2026;44(7_suppl):182\u2013182. https:\/\/doi.org\/10.1200\/JCO.2026.44.7_suppl.182.","journal-title":"J Clin Oncol"},{"key":"2355_CR43","doi-asserted-by":"publisher","unstructured":"Pavel M, Verslype C, Rocha P, Greystoke A, Chauhan A, Koevi J, et al. Obrixtamig (BI 764532) in patients (pts) with relapsed\/refractory delta-like ligand 3 (DLL3)-high expressing extrapulmonary neuroendocrine carcinoma (epNEC): dose expansion part of the phase II DAREON-5 trial. J Clin Oncol. 2026. https:\/\/doi.org\/10.1200\/JCO.2026.44.2_suppl.TPS648.","DOI":"10.1200\/JCO.2026.44.2_suppl.TPS648"},{"issue":"8","key":"2355_CR44","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1470-2045(24)00249-3","volume":"25","author":"S Tendler","year":"2024","unstructured":"Tendler S, Dunphy MP, Agee M, O\u2019Donoghue J, Aly RG, Choudhury NJ, et al. Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1\/2, first-in-human trial. Lancet Oncol. 2024;25(8):1015\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(24)00249-3.","journal-title":"Lancet Oncol"},{"key":"2355_CR45","doi-asserted-by":"publisher","unstructured":"Tendler S, Dunphy M, Gopalan A, O\u2019 Donoghue JA, Lyashchenko SK, Bodei L, et al. Imaging with [89 Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with neuroendocrine tumors of the prostate: a phase 1\/2, first-in-human trial. JCO. 2025;43(16_suppl). https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e15057.","DOI":"10.1200\/JCO.2025.43.16_suppl.e15057"},{"key":"2355_CR46","doi-asserted-by":"publisher","unstructured":"Tendler S, Dunphy MP, Agee M, O\u2019Donoghue J, Aly RG, Choudhury NJ, et al. First-in-human imaging with [89 Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate [Internet]. Radiol Imaging; 2024 [cited 2026 Mar 14]. https:\/\/doi.org\/10.1101\/2024.01.10.24301109.","DOI":"10.1101\/2024.01.10.24301109"},{"issue":"27","key":"2355_CR47","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO-25-00363","volume":"43","author":"M Wermke","year":"2025","unstructured":"Wermke M, Gambardella V, Kuboki Y, Felip E, Sanmamed MF, Alese OB, et al. Phase I dose-escalation results for the delta-like ligand 3\/CD3 IgG-like T-cell engager obrixtamig (BI 764532) in patients with delta-like ligand 3+ small cell lung cancer or neuroendocrine carcinomas. JCO. 2025;43(27):3021\u201331. https:\/\/doi.org\/10.1200\/JCO-25-00363.","journal-title":"JCO"},{"key":"2355_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac9459","author":"LR Saunders","year":"2015","unstructured":"Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015. https:\/\/doi.org\/10.1126\/scitranslmed.aac9459.","journal-title":"Sci Transl Med."},{"issue":"1","key":"2355_CR49","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1186\/s12967-024-05568-y","volume":"22","author":"S Lin","year":"2024","unstructured":"Lin S, Zhang Y, Yao J, Yang J, Qiu Y, Zhu Z, et al. DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models. J Transl Med. 2024;22(1):766. https:\/\/doi.org\/10.1186\/s12967-024-05568-y.","journal-title":"J Transl Med"},{"issue":"1","key":"2355_CR50","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","volume":"16","author":"CM Rudin","year":"2023","unstructured":"Rudin CM, Reck M, Johnson ML, Blackhall F, Hann CL, Yang JCH, et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol. 2023;16(1):66. https:\/\/doi.org\/10.1186\/s13045-023-01464-y.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"2355_CR51","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1158\/1535-7163.MCT-23-0701","volume":"23","author":"Q Guo","year":"2024","unstructured":"Guo Q, Gao B, Song R, Li W, Zhu S, Xie Q, et al. FZ-AD005, a novel DLL3-targeted antibody-drug conjugate with topoisomerase I inhibitor, shows potent antitumor activity in preclinical models. Mol Cancer Ther. 2024;23(10):1367\u201377. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0701.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2355_CR52","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","volume":"15","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers. 2023;15(3):713. https:\/\/doi.org\/10.3390\/cancers15030713.","journal-title":"Cancers"},{"issue":"22","key":"2355_CR53","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063\u201375. https:\/\/doi.org\/10.1056\/NEJMoa2307980.","journal-title":"N Engl J Med"},{"issue":"2","key":"2355_CR54","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395. https:\/\/doi.org\/10.1182\/blood-2014-05-552729.","journal-title":"Blood"},{"key":"2355_CR55","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/TCRM.S150524","volume":"15","author":"LL Riegler","year":"2019","unstructured":"Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. TCRM. 2019;15:323\u201335. https:\/\/doi.org\/10.2147\/TCRM.S150524.","journal-title":"TCRM."},{"issue":"9","key":"2355_CR56","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41585-025-01014-w","volume":"22","author":"C Boixareu","year":"2025","unstructured":"Boixareu C, Taha T, Venkadakrishnan VB, de Bono J, Beltran H. Targeting the tumour cell surface in advanced prostate cancer. Nat Rev Urol. 2025;22(9):569\u201389. https:\/\/doi.org\/10.1038\/s41585-025-01014-w.","journal-title":"Nat Rev Urol"},{"issue":"1","key":"2355_CR57","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/s41467-021-21615-4","volume":"12","author":"L Brady","year":"2021","unstructured":"Brady L, Kriner M, Coleman I, Morrissey C, Roudier M, True LD, et al. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat Commun. 2021;12(1):1426. https:\/\/doi.org\/10.1038\/s41467-021-21615-4.","journal-title":"Nat Commun"},{"issue":"3","key":"2355_CR58","doi-asserted-by":"publisher","first-page":"694","DOI":"10.21037\/tlcr-23-820","volume":"13","author":"RY Bellis","year":"2024","unstructured":"Bellis RY, Adusumilli PS, Amador-Molina A. DLL3-targeted CAR T-cell therapy in pre-clinical models for small cell lung cancer: safety, efficacy, and challenges. Transl Lung Cancer Res. 2024;13(3):694\u20138. https:\/\/doi.org\/10.21037\/tlcr-23-820.","journal-title":"Transl Lung Cancer Res."},{"issue":"3","key":"2355_CR59","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/jcph.2346","volume":"64","author":"D Zhou","year":"2024","unstructured":"Zhou D, Byers LA, Sable B, Smit MD, Sadraei NH, Dutta S, et al. Clinical pharmacology profile of AMG 119, the first chimeric antigen receptor T (CAR-T) cell therapy targeting delta-like ligand 3 (DLL3), in patients with relapsed\/refractory small cell lung cancer (SCLC). J Clin Pharma. 2024;64(3):362\u201370. https:\/\/doi.org\/10.1002\/jcph.2346.","journal-title":"J Clin Pharma"},{"issue":"7","key":"2355_CR60","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1158\/1078-0432.CCR-21-1533","volume":"28","author":"KM Tully","year":"2022","unstructured":"Tully KM, Tendler S, Carter LM, Sharma SK, Samuels ZV, Mandleywala K, et al. Radioimmunotherapy targeting delta-like ligand 3 in small cell lung cancer exhibits antitumor efficacy with low toxicity. Clin Cancer Res. 2022;28(7):1391\u2013401. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1533.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2355_CR61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2505785123","volume":"123","author":"S Tendler","year":"2026","unstructured":"Tendler S, De Gregorio R, Balderes P, Michel AL, Hoang TT, Bauer D, et al. Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers. Proc Natl Acad Sci USA. 2026;123(6):e2505785123. https:\/\/doi.org\/10.1073\/pnas.2505785123.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2355_CR62","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT06179069."},{"issue":"3","key":"2355_CR63","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41391-021-00332-5","volume":"24","author":"JE Berchuck","year":"2021","unstructured":"Berchuck JE, Viscuse PV, Beltran H, Aparicio A. Clinical considerations for the management of androgen indifferent prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):623\u201337. https:\/\/doi.org\/10.1038\/s41391-021-00332-5.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"2355_CR64","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.3390\/cancers12123792","volume":"12","author":"N Spetsieris","year":"2020","unstructured":"Spetsieris N, Boukovala M, Patsakis G, Alafis I, Efstathiou E. Neuroendocrine and aggressive-variant prostate cancer. Cancers. 2020;12(12):3792. https:\/\/doi.org\/10.3390\/cancers12123792.","journal-title":"Cancers"},{"issue":"5","key":"2355_CR65","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11912-017-0593-6","volume":"19","author":"PJ Vlachostergios","year":"2017","unstructured":"Vlachostergios PJ, Puca L, Beltran H. Emerging variants of castration-resistant prostate cancer. Curr Oncol Rep. 2017;19(5):32. https:\/\/doi.org\/10.1007\/s11912-017-0593-6.","journal-title":"Curr Oncol Rep"},{"issue":"16_suppl","key":"2355_CR66","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1200\/JCO.2025.43.16_suppl.5087","volume":"43","author":"H Ebrahimi","year":"2025","unstructured":"Ebrahimi H, Barragan-Carrillo R, Zugman M, Jaime-Casas S, Shah K, Castro DV, et al. Genomic landscape and clinical characteristics of patients (pts) with neuroendocrine prostate cancer (NEPC) with or without aggressive variant prostate cancer characterized by molecular signature (AVPC-MS). JCO. 2025;43(16_suppl):5087\u20135087. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.5087.","journal-title":"JCO"},{"issue":"1","key":"2355_CR67","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41467-023-36325-2","volume":"14","author":"T Hirz","year":"2023","unstructured":"Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14(1):663. https:\/\/doi.org\/10.1038\/s41467-023-36325-2.","journal-title":"Nat Commun"},{"issue":"10","key":"2355_CR68","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","volume":"18","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang Y, Ci X, Choi SYC, Crea F, Lin D, et al. Molecular events in neuroendocrine prostate cancer development. Nat Rev Urol. 2021;18(10):581\u201396. https:\/\/doi.org\/10.1038\/s41585-021-00490-0.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"2355_CR69","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.7150\/thno.92336","volume":"14","author":"T Zhang","year":"2024","unstructured":"Zhang T, Zhao F, Lin Y, Liu M, Zhou H, Cui F, et al. Integrated analysis of single-cell and bulk transcriptomics develops a robust neuroendocrine cell-intrinsic signature to predict prostate cancer progression. Theranostics. 2024;14(3):1065\u201380. https:\/\/doi.org\/10.7150\/thno.92336.","journal-title":"Theranostics."},{"issue":"6_Supplement","key":"2355_CR70","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.1158\/1538-7445.AM2024-5067","volume":"84","author":"R Watanabe","year":"2024","unstructured":"Watanabe R, Miura N, Kurata M, Kitazawa R, Kikugawa T, Saika T. Abstract 5067: exploring the genomic landscape of de novo neuroendocrine prostate cancer: insights for innovative therapies from spatial gene expression analysis. Can Res. 2024;84(6_Supplement):5067\u20135067. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-5067.","journal-title":"Can Res"},{"issue":"8","key":"2355_CR71","doi-asserted-by":"publisher","first-page":"T67","DOI":"10.1530\/ERC-21-0140","volume":"28","author":"H Beltran","year":"2021","unstructured":"Beltran H, Demichelis F. Therapy considerations in neuroendocrine prostate cancer: what next? Endocr Relat Cancer. 2021;28(8):T67-78. https:\/\/doi.org\/10.1530\/ERC-21-0140.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2355_CR72","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41392-022-01150-4","volume":"7","author":"Y Tian","year":"2022","unstructured":"Tian Y, Li Q, Yang Z, Zhang S, Xu J, Wang Z, et al. Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer. Sig Transduct Target Ther. 2022;7(1):346. https:\/\/doi.org\/10.1038\/s41392-022-01150-4.","journal-title":"Sig Transduct Target Ther."},{"issue":"1","key":"2355_CR73","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1038\/s41467-022-29517-9","volume":"13","author":"D Lissa","year":"2022","unstructured":"Lissa D, Takahashi N, Desai P, Manukyan I, Schultz CW, Rajapakse V, et al. Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models. Nat Commun. 2022;13(1):2023. https:\/\/doi.org\/10.1038\/s41467-022-29517-9.","journal-title":"Nat Commun"},{"issue":"15","key":"2355_CR74","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1158\/1078-0432.CCR-22-3743","volume":"29","author":"B Bhinder","year":"2023","unstructured":"Bhinder B, Ferguson A, Sigouros M, Uppal M, Elsaeed AG, Bareja R, et al. Immunogenomic landscape of neuroendocrine prostate cancer. Clin Cancer Res. 2023;29(15):2933\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3743.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2355_CR75","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13000-019-0827-z","volume":"14","author":"L Brcic","year":"2019","unstructured":"Brcic L, Kuchler C, Eidenhammer S, Pabst D, Quehenberger F, Gazdar AF, et al. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures. Diagn Pathol. 2019;14(1):47. https:\/\/doi.org\/10.1186\/s13000-019-0827-z.","journal-title":"Diagn Pathol"},{"key":"2355_CR76","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.lungcan.2020.07.026","volume":"147","author":"F Rojo","year":"2020","unstructured":"Rojo F, Corassa M, Mavroudis D, \u00d6z AB, Biesma B, Brcic L, et al. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer. 2020;147:237\u201343. https:\/\/doi.org\/10.1016\/j.lungcan.2020.07.026.","journal-title":"Lung Cancer"},{"issue":"6","key":"2355_CR77","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s11523-023-01008-x","volume":"18","author":"LC Bylsma","year":"2023","unstructured":"Bylsma LC, Pundole X, Ju CH, Hooda N, Movva N, Elkhouly E, et al. Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. Targ Oncol. 2023;18(6):821\u201335. https:\/\/doi.org\/10.1007\/s11523-023-01008-x.","journal-title":"Targ Oncol."},{"issue":"4","key":"2355_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104514","volume":"10","author":"K Csende","year":"2025","unstructured":"Csende K, Ferencz B, Boettiger K, Pozonec MD, Lantos A, Ferenczy A, et al. Comparative profiling of surgically resected primary tumors and their lymph node metastases in small-cell lung cancer. ESMO Open. 2025;10(4):104514. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104514.","journal-title":"ESMO Open"},{"issue":"4_suppl","key":"2355_CR79","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1200\/JCO.2024.42.4_suppl.121","volume":"42","author":"H Beltran","year":"2024","unstructured":"Beltran H, Dowlati A, Jain P, Johnson ML, Sanborn RE, Thompson JR, et al. Interim results from a phase 1\/2 study of HPN328, a tri-specific, half-life (T1\/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN). JCO. 2024;42(4_suppl):121\u2013121. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.121.","journal-title":"JCO"},{"issue":"16_suppl","key":"2355_CR80","doi-asserted-by":"publisher","first-page":"5012","DOI":"10.1200\/JCO.2024.42.16_suppl.5012","volume":"42","author":"RR Aggarwal","year":"2024","unstructured":"Aggarwal RR, Rottey S, Bernard-Tessier A, Mellado-Gonzalez B, Kosaka T, Stadler WM, et al. Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). J Clin Oncol. 2024;42(16_suppl):5012\u20135012. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.5012.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2355_CR81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12022-025-09854-3","volume":"36","author":"M Schmitt","year":"2025","unstructured":"Schmitt M, Bohnenberger H, Bartsch DK, Wagner DC, Litmeyer AS, Grass A, et al. DLL3 expression in neuroendocrine carcinomas and neuroendocrine tumours: insights from a multicentric cohort of 1294 pulmonary and extrapulmonary neuroendocrine neoplasms. Endocr Pathol. 2025;36(1):9. https:\/\/doi.org\/10.1007\/s12022-025-09854-3.","journal-title":"Endocr Pathol"},{"key":"2355_CR82","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00724","volume":"9","author":"R Thummalapalli","year":"2025","unstructured":"Thummalapalli R, Tendler S, Chou JF, Tarcan ZC, Porfido C, Willner J, et al. Delta-Like ligand 3 expression and functional imaging in gastroenteropancreatic neuroendocrine neoplasms. JCO Precis Oncol. 2025;9:e2500724. https:\/\/doi.org\/10.1200\/PO-25-00724.","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"2355_CR83","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2967\/jnumed.121.263221","volume":"63","author":"JA Korsen","year":"2022","unstructured":"Korsen JA, Kalidindi TM, Khitrov S, Samuels ZV, Chakraborty G, Gutierrez JA, et al. Molecular imaging of neuroendocrine prostate cancer by targeting delta-like ligand 3. J Nucl Med. 2022;63(9):1401\u20137. https:\/\/doi.org\/10.2967\/jnumed.121.263221.","journal-title":"J Nucl Med"},{"key":"2355_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1592291","volume":"16","author":"K Ji","year":"2025","unstructured":"Ji K, Guo L, Zuo D, Feng M, Chen X, Zhao Z, et al. Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer. Front Immunol. 2025;16:1592291. https:\/\/doi.org\/10.3389\/fimmu.2025.1592291.","journal-title":"Front Immunol"},{"issue":"1","key":"2355_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000785","volume":"8","author":"X Chen","year":"2020","unstructured":"Chen X, Amar N, Zhu Y, Wang C, Xia C, Yang X, et al. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth. J Immunother Cancer. 2020;8(1):e000785. https:\/\/doi.org\/10.1136\/jitc-2020-000785.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"2355_CR86","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S1470-2045(25)00480-2","volume":"26","author":"KG Paulson","year":"2025","unstructured":"Paulson KG, Lau SCM, Ahn MJ, Moskovitz M, Pogorzelski M, H\u00e4fliger S, et al. Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. Lancet Oncol. 2025;26(10):1300\u201311. https:\/\/doi.org\/10.1016\/S1470-2045(25)00480-2.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2355_CR87","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-025-09873-0","volume":"36","author":"I Ahmed","year":"2025","unstructured":"Ahmed I, Mohamed A, Savari O, Xue Y, Asa SL. Expression of DLL3 and SEZ6 in the spectrum of neuroendocrine neoplasia. Endocr Pathol. 2025;36(1):27. https:\/\/doi.org\/10.1007\/s12022-025-09873-0.","journal-title":"Endocr Pathol"},{"issue":"722","key":"2355_CR88","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf6732","volume":"15","author":"Y Yamada","year":"2023","unstructured":"Yamada Y, Venkadakrishnan VB, Mizuno K, Bakht M, Ku SY, Garcia MM, et al. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. Sci Transl Med. 2023;15(722):eadf6732. https:\/\/doi.org\/10.1126\/scitranslmed.adf6732.","journal-title":"Sci Transl Med"},{"issue":"8_Supplement_1","key":"2355_CR89","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.1158\/1538-7445.AM2025-4776","volume":"85","author":"T Yi","year":"2025","unstructured":"Yi T, Yang L, Hao K, Cao W, Qi Y, Gai J, et al. Abstract 4776: preclinical study of bispecific antibody drug conjugates (bsADCs) targeting DLL3 and SEZ6 demonstrated potent anti-tumor activity in small cell lung cancer (SCLC) xenograft models. Cancer Res. 2025;85(8_Supplement_1):4776\u20134776. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-4776.","journal-title":"Cancer Res"},{"issue":"8_Supplement_1","key":"2355_CR90","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1158\/1538-7445.AM2025-6081","volume":"85","author":"K Zhang","year":"2025","unstructured":"Zhang K, Yang L, Li P, Qi Y, Gai J, Du L, et al. Abstract 6081: bispecific antibody drug conjugates (bsADCs) targeting DLL3 and B7-H3 demonstrated potent anti-tumor activity in preclinical models of small cell lung cancer (SCLC). Cancer Res. 2025;85(8_Supplement_1):6081\u20136081. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-6081.","journal-title":"Cancer Res"},{"issue":"4","key":"2355_CR91","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","volume":"393","author":"G Mountzios","year":"2025","unstructured":"Mountzios G, Sun L, Cho BC, Demirci U, Baka S, G\u00fcm\u00fc\u015f M, et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med. 2025;393(4):349\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2502099.","journal-title":"N Engl J Med"},{"issue":"1","key":"2355_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00680-z","volume":"12","author":"L Bonstingl","year":"2024","unstructured":"Bonstingl L, Zinnegger M, Sallinger K, Pankratz K, M\u00fcller CT, Pritz E, et al. Advanced single-cell and spatial analysis with high-multiplex characterization of circulating tumor cells and tumor tissue in prostate cancer: unveiling resistance mechanisms with the CoDuCo in situ assay. Biomark Res. 2024;12(1):140. https:\/\/doi.org\/10.1186\/s40364-024-00680-z.","journal-title":"Biomark Res"},{"issue":"16_suppl","key":"2355_CR93","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1200\/JCO.2024.42.16_suppl.5015","volume":"42","author":"YW Chen","year":"2024","unstructured":"Chen YW, Xiu J, Poorman KA, Ryan CJ, Gilg B, Oberley MJ, et al. Clinical utility of transcriptomic signatures to identify androgen receptor and neuroendocrine signaling in prostate cancer. J Clin Oncol. 2024;42(16_suppl):5015\u20135015. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.5015.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2355_CR94","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70238","volume":"132","author":"H Dudipala","year":"2026","unstructured":"Dudipala H, Nazari SS, Werneck Da Cunha I, Coligado N, Baca Y, Wei S, et al. Molecular alteration profiles characterize intraductal carcinoma of the prostate. Cancer. 2026;132(1):e70238. https:\/\/doi.org\/10.1002\/cncr.70238.","journal-title":"Cancer"},{"issue":"1","key":"2355_CR95","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.1038\/s41467-025-60654-z","volume":"16","author":"K Mizuno","year":"2025","unstructured":"Mizuno K, Ku SY, Venkadakrishnan VB, Bakht MK, Sigouros M, Chan J, et al. Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer. Nat Commun. 2025;16(1):5543. https:\/\/doi.org\/10.1038\/s41467-025-60654-z.","journal-title":"Nat Commun"},{"key":"2355_CR96","doi-asserted-by":"publisher","unstructured":"Lai JI, Peng YC, Chang PMH, Chang YH, Chung HJ, Huang YH, et al. Real-world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma. J Chin Med Assoc. 2025;88(4):283\u2013289. https:\/\/doi.org\/10.1097\/JCMA.0000000000001209.","DOI":"10.1097\/JCMA.0000000000001209"},{"issue":"6","key":"2355_CR97","doi-asserted-by":"publisher","first-page":"232","DOI":"10.14740\/wjon1423","volume":"12","author":"PJ Vlachostergios","year":"2021","unstructured":"Vlachostergios PJ, Karathanasis A, Papandreou CN, Tzortzis V. Early mRNA expression of neuroendocrine differentiation signals predicts recurrence after radical prostatectomy: a transcriptomic analysis. World J Oncol. 2021;12(6):232\u20139. https:\/\/doi.org\/10.14740\/wjon1423.","journal-title":"World J Oncol."},{"issue":"27","key":"2355_CR98","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2203820119","volume":"119","author":"JA Korsen","year":"2022","unstructured":"Korsen JA, Gutierrez JA, Tully KM, Carter LM, Samuels ZV, Khitrov S, et al. Delta-like ligand 3\u2013targeted radioimmunotherapy for neuroendocrine prostate cancer. Proc Natl Acad Sci USA. 2022;119(27):e2203820119. https:\/\/doi.org\/10.1073\/pnas.2203820119.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6_suppl","key":"2355_CR99","doi-asserted-by":"publisher","first-page":"TPS197","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS197","volume":"40","author":"RR Aggarwal","year":"2022","unstructured":"Aggarwal RR, Rottey S, Aparicio A, Greil R, Reimers MA, Sandhu SK, et al. Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTEimmune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC). J Clin Oncol. 2022;40(6_suppl):TPS197\u2013TPS197. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS197.","journal-title":"J Clin Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02355-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02355-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02355-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:02:23Z","timestamp":1788242543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02355-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":99,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2355"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02355-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Silke Gillessen received personal honoraria for participation in advisory boards for Sanofi, Orion, Roche, Amgen, MSD; other honoraria from RSI (Televisione Svizzera Italiana); invited speaker for ESMO, Swiss group for Clinical Cancer Research (SAKK), Swiss Academy of Multidisciplinary oncology (SAMO), Orikata academy research group, China Anti-Cancer Association Genitourinary Oncology Committee (CACA-GU); Speaker\u2019s bureau for Janssen Cilag; travel grant from ProteoMEdiX; institutional honoraria for advisory boards for Bayer, Janssen Cilag, Roche, AAA International including Independent Data Monitoring Committee and IDMC and Steering Committee member for Amgen, Menarini Silicon Biosystems, Astellas Pharma, Tolero Pharmaceuticals, MSD, Pfizer, Telixpharma, BMS and Orion; patent royalties and other intellectual property for a research method for biomarker WO2009138392. Fabio Turco and Martino Pedrani received a travel grant from Bayer. Gunhild von Amsberg received personal honoraria for consultancy, advisory boards or discussion of off-label drug use from Amgen, Astellas, AstraZeneca, Bayer, BMS, Ipsen, Janssen (Johnson & Johnson), Lilly, MSD, Merck, Novartis, Pfizer, Roche. She received institutional research funding for industry sponsored clinical trials by Roche Pfizer, BMS, MSD\/Merck, AstraZeneca, Pfizer, Exelixis, Ipsen, Lilly, Novartis, AvenCell, Bayer, Astellas. Himisha Beltran has served as consultant\/advisory board member for Janssen, Merck, Pfizer, Amgen, Bayer, Daiichi Sankyo, Astra Zeneca, Novartis, Abbvie, and has received research funding (to institution) from Janssen, Bristol Myers Squibb, Circle Pharma, Daiichi Sankyo, Novartis, Abbvie. Markus Joerger received institutional honoraria for advisory roles from Novartis, Astra Zeneca, Bayer, BMS, MSD, Roche, Sanofi; research funding from Swiss Cancer Research; travel grants from Roche, Sanofi, PharmaMar. Tarek Taha reports institutional support for attending meetings and\/or travel from Pfizer, and receiving honoraria from BMS, MSD, Merck-Serono and Pfizer. Ilaria Colombo declares institutional funding for clinical trials as PI from\u00a0AstraZeneca, Merck Sharp & Dohme, Vivesto, Tolremo, Orion, Bayer, Incyte, Debiopharm, PharmaMar; personal honoraria for consultancy for Biontech; institutional honoraria for consultancy\/advisor role from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme, AbbVie, Incyte, Beigene. Fabio Turco reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Silvio Grasso Consulting (institutional), SAKK (institutional), Merck (institutional), Novartis (institutional), Bayer (individual) and MSD (individual); support for attending meetings or travel from Bayer (individual); and participation on a data safety monitoring board or advisory board for Bayer (individual) and Telix (individual). Giovanna Pecoraro, Alberto De Giorgi, Giulia Montelatici, Giuseppe Salfi, Hui-Ming Lin, Johann de Bono, Rahul Raj Aggarwal, and Martina Imbimbo declare the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study concept and design: Pedrani, Pecoraro, Gillessen. Acquisition of data: Salfi, Pedrani, Pecoraro, Montelatici, De Giorgi. Analysis and interpretation of data: Pedrani, Pecoraro, Gillessen. Drafting of the manuscript Pecoraro, Pedrani, Lin. Critical revision of the manuscript for important intellectual content: Turco, Taha, Beltran, de Bono, Aggarwal, von Amsberg, Joerger, Imbimbo, Colombo, Gillessen, Pedrani. Statistical analysis None. Obtaining funding None. Administrative, technical, or material support None. Supervision Pedrani, Gillessen.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}